NCT05334056 is a clinical trial of Cocaine Nasal in Cocaine Adverse Reaction, sponsored by Rigshospitalet, Denmark.

Who is sponsoring NCT05334056?

NCT05334056 is sponsored by Rigshospitalet, Denmark.

What drugs are being tested in NCT05334056?

Interventions in NCT05334056: Cocaine Nasal.

What condition does NCT05334056 study?

NCT05334056 studies Cocaine Adverse Reaction.

Is NCT05334056 still recruiting?

NCT05334056 is currently completed. Last updated 1 June 2023.

Last reviewed 2023-06-01 · How we verify

NCT05334056

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug Test Detection of Cocaine for Nasal Intubation

Completed Last updated 1 June 2023

What this trial tests

trial testing Cocaine Nasal in Cocaine Adverse Reaction in 27 participants. Completed in 27 May 2023.

Timeline

22 March 2023

Primary endpoint
27 May 2023

27 May 2023

Quick facts

Lead sponsor	Rigshospitalet, Denmark
Status	Completed
Study type	OBSERVATIONAL
Enrollment	27
Start date	22 March 2023
Primary completion	27 May 2023
Estimated completion	27 May 2023
Sites	1 location across Denmark

Drugs / interventions tested

Cocaine Nasal

Conditions studied

Cocaine Adverse Reaction — all drugs for Cocaine Adverse Reaction →

Sponsor

Rigshospitalet, Denmark

Who can join

18 and older, any sex, with Cocaine Adverse Reaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to determine whether it is possible to detect traces above national cut-offs of either cocaine's main metabolite benzoylecgonine in saliva or cocaine in blood 24 hours after administering 2 ml of 40 mg/ml cocaine-saline to the nasal mucosa. The investigators hypothesize that the level of cocaine's main metabolite bezoylecgonine in saliva after cocaine administered for anesthetic purposes will be below detection limits after 24 hours.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

NCT07401368 — Clinicians' Trust in AI-Based Fetal Growth Estimates · NA · not yet recruiting
NCT07442357 — The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial · NA · not yet recruiting
NCT07528729 — Alcohol as a Modifiable Risk Factor for Atrial Fibrillation · NA · not yet recruiting
NCT07511439 — Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission · Phase 4 · not yet recruiting
NCT07467187 — Invasive Home Ventilation in Denmark · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05334056 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rigshospitalet, Denmark
Last refreshed: 1 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05334056.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing